Written by: Brittany M. Penn

Quest Diagnostics recently announced a multi-faceted collaboration with PathAI to improve diagnoses in cancer and other diseases using AI pathology innovations.

Under a first agreement, Quest will acquire some of the assets of PathAI Diagnostics that provide anatomic and digital pathology laboratory services. This will support Quest’s specialty pathology businesses. Under a second agreement, Quest will license PathAI’s digital pathology management system, AISight™.

Regarding the collaboration, Kristie Dolan, Quest’s Senior Vice President of Oncology, stated:

According to Quest’s press release, the collaboration will increase profits for its anatomic pathology services by allowing Quest to enter into more profitable areas such as dermatopathology as well as gastrointestinal and urological diseases. The collaboration is also planned to give provider customers of PathAI Diagnostics access to Quest’s industry-leading clinical test menu, thousands of patient service centers in the U.S., and broad health plan relationships.